PTC Therapeutics director sells 12,000 shares

The director's options had an expiration date of January 2, 2027.

Rhea-AI Filing Summary

PTC Therapeutics, Inc. director Glenn Jr. MD, PhD Steele exercised 12,000 options at an exercise price of $11.23 per share on September 30, 2026, acquiring 12,000 common shares, then sold 12,000 common shares at $65.16 per share that day. The transactions were effected under a written Rule 10b5-1 plan adopted March 9, 2026. The options were currently exercisable; the reported option balance after the transaction was 0.

Insider Trade Summary 10b5-1

Exercise and Sale: 12,000 shares ($647K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider STEELE GLENN JR MD PHD

Role Director

Sold 12,000 shs ($782K)

Approx. gross sale proceeds $782K

Approx. exercise cost $135K

Approx. pre-tax spread $647K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F2	12,000	$0.00	$0.00
Exercise	Common Stock F1	12,000	$11.23	$135K
Sale	Common Stock F1	12,000	$65.16	$782K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 22,500 shares (Direct)

Footnotes (2)

1. F1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 9, 2026
2. F2. Currently exercisable.

Key Figures

Options exercised: 12,000 options Exercise price: $11.23 per share Shares sold: 12,000 shares +2 more

5 metrics

Options exercised 12,000 options September 30, 2026

Exercise price $11.23 per share Options exercised September 30, 2026

Shares sold 12,000 shares September 30, 2026

Sale price $65.16 per share September 30, 2026

Options following transaction 0 options Reported after the September 30, 2026 transaction

Key Terms

Rule 10b5-1 plan, Stock Option (Right to Buy), Currently exercisable

3 terms

Rule 10b5-1 plan regulatory

"written Rule 10b5-1 plan adopted by the Reporting Person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Stock Option (Right to Buy) technical

"Stock Option (Right to Buy)"

Currently exercisable technical

"Currently exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PTCT shares did director Glenn Jr. MD, PhD Steele sell, and at what price?

Glenn Jr. MD, PhD Steele sold 12,000 common shares at $65.16 per share on September 30, 2026, after exercising options to acquire 12,000 shares at an exercise price of $11.23 per share. The transactions were effected under a written Rule 10b5-1 plan adopted March 9, 2026.

When did the PTCT options in the transaction expire?

The options were currently exercisable and had an expiration date of January 2, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 05:20 PM Accepted by SEC EDGAR 10/02/2026 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STEELE GLENN JR MD PHD

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2026		M(1)		12,000	A	$11.23	34,500	D
Common Stock	09/30/2026		S(1)		12,000	D	$65.16	22,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.23	09/30/2026		M(1)			12,000	(2)	01/02/2027	Common Stock	12,000	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 9, 2026

2. Currently exercisable.

	/s/ Avraham S. Adler, Attorney-in-Fact	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)